|
MechanismHistamine receptor agonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date07 Oct 2008 |
Target- |
MechanismImmunomodulators |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT in Adults With Birch Pollen Allergic Rhinitis
A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping Peptides Derived from Bet v 1, in Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis
A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ASSESS THE EFFICACY AND TOLERABILITY OF TWO DOSING REGIMENS OF ALLERT, A COMBINATION OF CONTIGUOUS OVERLAPPING PEPTIDES DERIVED FROM BET V 1, IN ADULTS WITH BIRCH POLLEN ALLERGIC RHINITIS/RHINOCONJUNCTIVITIS
A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ASSESS THE EFFICACY AND TOLERABILITY OF TWO DOSING REGIMENS OF ALLERT, A COMBINATION OF CONTIGUOUS OVERLAPPING PEPTIDES DERIVED FROM BET V 1, IN ADULTS WITH BIRCH POLLEN ALLERGIC RHINITIS/RHINOCONJUNCTIVITIS
100 Clinical Results associated with Anergis SA
0 Patents (Medical) associated with Anergis SA
100 Deals associated with Anergis SA
100 Translational Medicine associated with Anergis SA